Canopy Growth Corporation (NASDAQ:CGC – Get Free Report) has received a consensus recommendation of “Hold” from the six brokerages that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and two have assigned a buy recommendation to the company.
CGC has been the topic of a number of analyst reports. Wall Street Zen downgraded Canopy Growth from a “hold” rating to a “sell” rating in a research report on Sunday, March 29th. Weiss Ratings raised Canopy Growth from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday. Alliance Global Partners reissued a “neutral” rating on shares of Canopy Growth in a research report on Saturday, February 7th. Canaccord Genuity Group initiated coverage on Canopy Growth in a research report on Friday, March 27th. They set a “buy” rating on the stock. Finally, ATB Cormark Capital Markets raised Canopy Growth from a “strong sell” rating to a “moderate buy” rating in a research report on Tuesday, March 17th.
View Our Latest Analysis on Canopy Growth
Institutional Investors Weigh In On Canopy Growth
Canopy Growth Price Performance
Canopy Growth stock opened at $1.04 on Friday. Canopy Growth has a 12 month low of $0.84 and a 12 month high of $2.38. The stock’s 50 day moving average is $1.07 and its 200-day moving average is $1.14. The company has a current ratio of 5.34, a quick ratio of 4.26 and a debt-to-equity ratio of 0.30. The company has a market capitalization of $420.28 million, a price-to-earnings ratio of -0.80 and a beta of 0.77.
Canopy Growth Company Profile
Canopy Growth Corporation is a leading Canadian cannabis company engaged in the production, distribution and sale of both medical and recreational cannabis products. Headquartered in Smiths Falls, Ontario, the company cultivates a diversified portfolio of offerings that includes dried flower, pre-rolled joints, oils, softgel capsules and edibles. Canopy Growth also markets derivative products such as beverages and wellness formulations under a range of brands, aiming to serve both patient and adult-use markets.
The company operates through multiple subsidiaries, including Tweed Inc, Spectrum Therapeutics and Tokyo Smoke, each targeting distinct consumer segments.
Featured Stories
- Five stocks we like better than Canopy Growth
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Canopy Growth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Canopy Growth and related companies with MarketBeat.com's FREE daily email newsletter.
